CGON
CG Oncology, Inc. Common stockNASDAQHealthcare$67.48+1.03%ClosedMarket Cap: $5.70B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.94
P/S
1411.78
EV/EBITDA
-33.94
DCF Value
$-2.20
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-15.0%
Operating Margin
-4722.1%
Net Margin
-3985.0%
ROE
-22.9%
ROA
-20.3%
ROIC
-25.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.3M | $-41.3M | $-0.52 |
| FY 2025 | $4.0M | $-161.0M | $-2.08 |
| Q3 2025 | $1.7M | $-43.8M | $-0.57 |
| Q2 2025 | $0.00 | $-41.4M | $-0.54 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2026-02-27Truist SecuritiesBuy
2026-02-10RBC CapitalOutperform
2026-01-21Piper SandlerOverweight
2026-01-16RBC CapitalOutperform
2025-11-17Trading Activity
Insider Trades
View AllMulay Jamesdirector
SellTue Mar 17
Mulay Jamesdirector
SellTue Mar 17
Mulay Jamesdirector
SellTue Mar 17
Kuan Arthurdirector, officer: Chief Executive Officer
SellFri Mar 13
Kuan Arthurdirector, officer: Chief Executive Officer
SellFri Mar 13
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.70
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.